AMCP is writing to express our serious concerns regarding the inclusion of Section 11, Biological Product Innovation in the FDA and NIH Workforce Authorities Modernization Act (S. 2700)— part of the Senate Innovations legislation marked up in the HELP Committee.
The Academy of Managed Care Pharmacy (AMCP) believes that abuse-deterrent opioid analgesic drug products should be used in a clinically appropriate manner; however, we are opposed to Sub. H.B. No. 248 as it requires special consideration for this class of drugs.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to submit comments for the record on the hearing titled “The Obama Administration’s Medicare Drug Experiment: The Patient and Doctor Perspective” scheduled for May 17, 2016.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) Center for Medicare and Medicaid Innovation (CMMI) for the opportunity to provide comments in response to the proposed rule titled “Medicare Program; Part B Drug Payment Model (CMS1670-P)” published in the Federal Register on March 11, 2016.
The Academy of Managed Care Pharmacy (AMCP) is opposed to the prior authorization language under Article 25 – Health Care in Senate File No. 2356, the Senate Omnibus Supplemental Appropriations Bill because it restricts a health benefit plan’s ability to manage its formulary, and it establishes unreasonable standards for the use of prior authorization by health benefit plans. Instead, it replaces these managed care tools with a government mandated design.
The Academy of Managed Care Pharmacy (AMCP) is opposed to the prior authorization language under Article 25 – Health Care in Senate File No. 2356, the Senate Omnibus Supplemental Appropriations Bill because it restricts a health benefit plan’s ability to manage its formulary, and it establishes unreasonable standards for the use of prior authorization by health benefit plans. Instead, it replaces these managed care tools with a government mandated design.
The Academy of Managed Care Pharmacy (AMCP) is writing to express its opposition to certain provisions of H.B. No. 254. AMCP opposes the practitioner notification requirements, which would place an unnecessary burden on the substitution of an interchangeable biological drug product. In addition, AMCP also opposes the new definition of “interchangeable biological product” included in the bill, which is not consistent with the Food and Drug Administration (FDA) definition.